Listen Listen
Add to my selection
  • History
  • Technical informations
Share Print

TAGRISSO

Medicine - Posted on May 30 2022
Active substance (DCI)
  • osimertinib
history (4)
  • Economic analysis
    1/19/22

    TAGRISSO (osimertinib) - Cancer bronchique non à petites cellules (CBNPC)
    Key points Favourable opinion for reimbursement only in the adjuvant treatment after complete tumour resection and after adj...
    CAV :
    54321
    icône flèche
  • 3/20/20

    TAGRISSO (osimertinib)
    Key points Favourable opinion for reimbursement as monotherapy in the first-line treatment of adult patients with locally ad...
    CAV :
    54321
    icône flèche
  • Economic analysis
    9/13/17

    TAGRISSO (osimertinib), tyrosine kinase inhibitor
    Substantial actual benefit and minor improvement compared with chemotherapy combining a platinum salt with pemetrexed in pat...
    CAV :
    54321
    icône flèche
  • Economic analysis
    9/21/16

    TAGRISSO (osimertinib), tyrosine kinase inhibitor
    No clinical benefit demonstrated in the treatment of locally-advanced or metastatic non-small cell lung cancer with EGFR T79...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01EB04
Manufacturer
ASTRAZENECA
Presentation

TAGRISSO 40 mg, comprimés pelliculés
30 plaquettes aluminium de 1 comprimé - (Code CIP : 34009 300 476 4 4)

TAGRISSO 80 mg, comprimés pelliculés
30 plaquettes aluminium de 1 comprimé - (Code CIP : 34009 300 476 5 1)

All our publications
    Drug therapy Health economics Respiratory tract cancers
  • fr Français
  • en English
eNq1mE1z2jAQhu/8Co8PvWEbkw/T2mRamrTMJFOahGmnF0bYC4gaydEHkPz6ypg0pCM3iUBHLPPuenf16B3FZ+tF7iyBcUxJ4ra8wHWApDTDZJq4w9uLZuSedRvxHC3R7muRF4xaUct10hxxnrjlujcGRLj38+ryMygFYG634cR0PIdUPHtPCpx7XxGfXaGifMeJlxRnzgLEjGaJW0ixeerEXDCVR3dF2W9eoBRif/tkd3U+Otp9Hvul2CtUJQd2ichUKwrESDOVjAERPSRgStm9VnqSjsLo9CQIIqMQmF8Dp5KlMEBiNmB0iTPI9JFQzsEoyGSV3QBb5iDKIFpxf54uuJE4mqP1Ndz19Ul/VKs9sRbNoNk6Oe1EURC2wqOwYxSK7ZRKPzzqI/yiYNko7ETt4/DEB+ILNGWYc2rYnwFlAuWWOoN57/mMWYrD4O7FCcgwL3J07815YVoqxJBaBqZIYO9Dyi+4ZYpNuarZP/pE5rn/xqyHW3JYyrgEU49KImoAMrwxLUSPEgHr+o6aMU+st7OIgR9O9oESPe8Hcpzj1BRrCjwSuBhe9+updmggfEIchsweEX5gktEVPzxpdjtrKftiA0utaDFqB8dRp21+vP9SM1RzzJxLRgvwFYAw34crfTKh+xJFjaVe6nEoDzqPG99DU5RDjfMZGQJGDeKjUbM26va2UbWgFf1yfms6It8lsPubzU+tNM6S3eaaAdgG1dVMvpR7tXWTv9v0HVoUHx5ddWLooCvRVxjoo6gdms0/0+NmJkTB3/v+arXyZog3OVJl9Sbs/0fCmbYKh6iE4u9TY+35fCueoPJIFX4tpT6uDtW3tdJ0G7/kGvZ1wtv/bx23NoZgEvboRUV8a1zunx8e9U822Frag2e0sRdmY1mRwJTYslFyrGf0voeLai25YIoR3yYTXHMDUzuasV/d/nQbsV/e/HQbfwD5Fw2M
1K8uhMbuC9aJqyDA